Challenges in cancer drug approval include the complexity of cancer biology, patient diversity, and the need for long-term follow-up to assess the treatment's effectiveness and safety. Additionally, balancing the urgency of providing new treatments to patients with the rigorous evaluation required to ensure safety and efficacy can be difficult. High costs and lengthy development timelines also pose significant challenges.
